Lantheus Q4 revenue $406.8M, adj EPS $1.67; narrows focus to PET radiodiagnostics

Lantheus Holdings, Inc.

2025-FY EPS reported $3.41 revenue$1,541,609,000

Worldwide revenue $406.8M (+4% YoY); FY2025 revenue $1.54B; GAAP diluted EPS $0.82 Q4, $3.41 FY.
Adjusted diluted EPS $1.67 Q4 (+4.7% YoY), $6.08 FY; PYLARIFY sales $240.2M (-9.7%).
Company sharpens focus on innovative PET radiodiagnostics; pursuing alternatives for radiotherapeutic assets; completed SPECT divestiture to SHINE.
FY2026 guidance: revenue $1.4B-$1.45B, adjusted diluted EPS $5.00-$5.25.
Repurchased $100M of stock in Q4; cash and equivalents $359.1M after acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.